Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma.
hepatocellular carcinoma
intermediate stage
surgical indicator
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
24
01
2023
received:
16
12
2022
accepted:
24
01
2023
medline:
10
2
2023
pubmed:
10
2
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
Recent advances in treatment modalities have been made, limiting the indication of hepatic resection in the treatment strategy for hepatocellular carcinoma (HCC) patients. This retrospective study investigated the significance of multiplication of tumor maximum diameter and number (MDN) as a surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC. A total of 49 patients with Barcelona Clinic Liver Cancer intermediate-stage HCC who underwent curative hepatic resection between 2000 and 2020 were enrolled in this study. Prognostic factors of overall survival and disease-free survival, including the product of MDN, were analyzed. Patients with MDN >12 experienced significantly worse prognosis compared with those with MDN ≤12 (p = 0.0395), and 5-year overall survival rates after hepatic resection were 60.0% and 23.4%, respectively. Furthermore, the disease-free survival rate of patients with MDN >12 was significantly worse compared with those with MDN ≤12 (p = 0.0049), and all patients with MDN >12 experienced recurrence within 3 years after hepatic resection. In the multivariate analysis, MDN >12 was identified as the only independent prognostic factor of both overall survival and disease-free survival. In addition, patients with MDN >12 suffered from uncontrollable recurrence by locoregional treatment, such as more than four intrahepatic and extrahepatic recurrences, after hepatic resection. MDN index might be a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC, and influence clinical decision-making for individual treatment strategies.
Types de publication
Journal Article
Langues
eng
Pagination
531-539Subventions
Organisme : Grant-in-Aid for Scientific Research
ID : 20K08957
Organisme : Research Program on Hepatitis of the Japanese Foundation for Multidisciplinary Treatment of Cancer, the Japan Agency for Medical Research and Development
ID : 22fk0210103h0001
Organisme : Research Program on Hepatitis of the Japanese Foundation for Multidisciplinary Treatment of Cancer, the Japan Agency for Medical Research and Development
ID : 22fk0210103s0201
Informations de copyright
© 2023 Japan Society of Hepatology.
Références
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncol. 2010;15((Suppl 4)):5-13. https://doi.org/10.1634/theoncologist.2010-S4-05
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. https://doi.org/10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73. https://doi.org/10.1016/S0140-6736(18)30207-1
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113-22. https://doi.org/10.1007/s00535-019-01642-1
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. IMbrave150 investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905. https://doi.org/10.1056/NEJMoa1915745
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Hepatology. 2022;76(4):862-73. https://doi.org/10.1016/j.jhep.2021.11.030
Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109-13. https://doi.org/10.1111/hepr.13411
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181-223. https://doi.org/10.1159/000514174
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.jhep.2021.11.018
Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma. Int J Mol Sci. 2021;22(19):10271. https://doi.org/10.3390/ijms221910271
Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3(5):100347. https://doi.org/10.1016/j.jhepr.2021.100347
Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma. World J Gastroenterol. 2022;28(4):432-48. https://doi.org/10.3748/wjg.v28.i4.432
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35-43. https://doi.org/10.1016/S1470-2045(08)70284-5
Yamamoto M, Kobayashi T, Hashimoto M, Kuroda S, Kawaoka T, Aikata H, et al. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. BMC Cancer. 2021;21(1):668. https://doi.org/10.1186/s12885-021-08421-3
Zhaohui Z, Shunli S, Bin C, Shaoqiang L, Yunpeng H, Ming K, et al. Hepatic resection provides survival benefit for selected intermediate-stage (BCLC-B) hepatocellular carcinoma patients. Cancer Res Treat. 2019;51(1):65-72. https://doi.org/10.4143/crt.2018.038
Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32(4):356-68. https://doi.org/10.1111/tri.13391
Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, Kinoshita M, et al. Prognostic value of expanded liver transplantation criteria-the 5-5-500 rule-in patients with hepatic resection for intermediate-stage hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2020;27(10):682-9. https://doi.org/10.1002/jhbp.792
Yoshimoto T, Morine Y, Imura S, Ikemoto T, Iwahashi S, Saito YU, et al. Maximum diameter and number of tumors as a new prognostic indicator of colorectal liver metastases. In: Vivo, 31(3); 2017. p. 419-23. https://doi.org/10.21873/invivo.11076
Saito Y, Imura S, Morine Y, Ikemoto T, Yamada S, Shimada M. Preoperative prognostic nutritional index predicts short- and long-term outcomes after liver resection in patients with hepatocellular carcinoma. Oncol Lett. 2021;21(2):153. https://doi.org/10.3892/ol.2020.12414
Kakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, et al. Surgical outcomes in gastroenterological surgery in Japan: report of the national clinical Database 2011-2018. Ann Gastroenterol Surg. 2020;4(3):250-74. https://doi.org/10.1002/ags3.12324
Xiangfei M, Yinzhe X, Yingwei P, Shichun L, Weidong D. Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc. 2019;33(8):2396-418. https://doi.org/10.1007/s00464-019-06781-3
Wang ZY, Chen QL, Sun LL, He SP, Luo XF, Huang LS, et al. Laparoscopic versus open major liver resection for hepatocellular carcinoma: systematic review and meta-analysis of comparative cohort studies. BMC Cancer. 2019;19(1):1047. https://doi.org/10.1186/s12885-019-6240-x
Hendi M, Lv J, Cai XJ. Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma: a systematic literature review. Medicine (Baltim). 2021;100(50):e27826. https://doi.org/10.1097/MD.0000000000027826
Wang Q, Li HJ, Dai XM, Xiang ZQ, Zhu Z. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: systematic review and meta-analysis of propensity-score matched studies. Int J Surg. 2022;105:106821. https://doi.org/10.1016/j.ijsu.2022.106821
Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541-65. https://doi.org/10.6004/jnccn.2021.0022
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-80. https://doi.org/10.1002/hep.29086
Vogel A, Martinelli E, Vogel A, Cervantes A, Chau I, Daniele B, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(6):801-5. https://doi.org/10.1016/j.annonc.2021.02.014
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38. https://doi.org/10.1055/s-2007-1007122
Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-59. https://doi.org/10.1055/s-0032-1329906
Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi's subclassification (Kinki criteria). Dig Dis. 2015;33(6):751-8. https://doi.org/10.1159/000439290
Iida H, Kaibori M, Hirokawa F, Inoue Y, Ueno M, Matsui K, et al. New hepatic resection criteria for intermediate-stage hepatocellular carcinoma can improve long-term survival: a retrospective, multicenter collaborative study. Asian Pac J Cancer Prev APJCP. 2020;21(10):2903-11. https://doi.org/10.31557/APJCP.2020.21.10.2903